Goldman Sachs’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.7M | Buy |
1,150,932
+345,156
| +43% | +$10.5M | ﹤0.01% | 1949 |
|
|
2026
Q1 | $27.3M | Sell |
805,776
-228,198
| -22% | -$6.47M | ﹤0.01% | 2145 |
|
|
2025
Q4 | $28.1M | Buy |
1,033,974
+229,208
| +28% | +$8.04M | ﹤0.01% | 2048 |
|
|
2025
Q3 | $32.3M | Buy |
804,766
+156,705
| +24% | +$5.89M | ﹤0.01% | 1800 |
|
|
2025
Q2 | $21.6M | Sell |
648,061
-10,591
| -2% | -$321K | ﹤0.01% | 2063 |
|
|
2025
Q1 | $19.3M | Buy |
658,652
+91,482
| +16% | +$3.03M | ﹤0.01% | 2066 |
|
|
2024
Q4 | $18.6M | Buy |
567,170
+90,513
| +19% | +$4.25M | ﹤0.01% | 2197 |
|
|
2024
Q3 | $21.2M | Sell |
476,657
-72,346
| -13% | -$3.29M | ﹤0.01% | 2019 |
|
|
2024
Q2 | $23.7M | Buy |
549,003
+9,421
| +2% | +$340K | ﹤0.01% | 1751 |
|
|
2024
Q1 | $15.8M | Sell |
539,582
-68,356
| -11% | -$1.83M | ﹤0.01% | 2039 |
|
|
2023
Q4 | $13.5M | Sell |
607,938
-197,499
| -25% | -$4.43M | ﹤0.01% | 2250 |
|
|
2023
Q3 | $19.9M | Buy |
805,437
+5,825
| +0.7% | +$154K | ﹤0.01% | 1799 |
|
|
2023
Q2 | $22.6M | Sell |
799,612
-164,550
| -17% | -$4.09M | ﹤0.01% | 1740 |
|
|
2023
Q1 | $22.1M | Sell |
964,162
-598,870
| -38% | -$15.9M | 0.01% | 1732 |
|
|
2022
Q4 | $43.9M | Sell |
1,563,032
-197,173
| -11% | -$5.56M | 0.01% | 1275 |
|
|
2022
Q3 | $49.8M | Buy |
1,760,205
+85,392
| +5% | +$2.29M | 0.01% | 1123 |
|
|
2022
Q2 | $37.1M | Sell |
1,674,813
-142,388
| -8% | -$3.22M | 0.01% | 1353 |
|
|
2022
Q1 | $52.9M | Sell |
1,817,201
-63,730
| -3% | -$1.95M | 0.01% | 1228 |
|
|
2021
Q4 | $61.8M | Buy |
1,880,931
+82,832
| +5% | +$3.33M | 0.01% | 1171 |
|
|
2021
Q3 | $83M | Sell |
1,798,099
-90,045
| -5% | -$4.35M | 0.02% | 866 |
|
|
2021
Q2 | $104M | Buy |
1,888,144
+571,520
| +43% | +$32M | 0.02% | 710 |
|
|
2021
Q1 | $68M | Sell |
1,316,624
-521,025
| -28% | -$25.8M | 0.02% | 925 |
|
|
2020
Q4 | $79.6M | Sell |
1,837,649
-354,840
| -16% | -$14M | 0.02% | 766 |
|
|
2020
Q3 | $76.7M | Buy |
2,192,489
+198,826
| +10% | +$8.71M | 0.02% | 722 |
|
|
2020
Q2 | $107M | Sell |
1,993,663
-127,172
| -6% | -$5.89M | 0.03% | 526 |
|
|
2020
Q1 | $75.2M | Sell |
2,120,835
-172,691
| -8% | -$7.98M | 0.03% | 634 |
|
|
2019
Q4 | $110M | Buy |
2,293,526
+1,013,620
| +79% | +$38.3M | 0.03% | 648 |
|
|
2019
Q3 | $41.5M | Sell |
1,279,906
-245,540
| -16% | -$10.2M | 0.01% | 1232 |
|
|
2019
Q2 | $76.1M | Sell |
1,525,446
-110,627
| -7% | -$5.91M | 0.02% | 851 |
|
|
2019
Q1 | $110M | Buy |
1,636,073
+320,626
| +24% | +$18.7M | 0.03% | 600 |
|
|
2018
Q4 | $60.7M | Buy |
1,315,447
+74,132
| +6% | +$4.58M | 0.02% | 947 |
|
|
2018
Q3 | $95.7M | Sell |
1,241,315
-14,402
| -1% | -$1.16M | 0.02% | 795 |
|
|
2018
Q2 | $106M | Buy |
1,255,717
+104,413
| +9% | +$9.11M | 0.03% | 694 |
|
|
2018
Q1 | $94.2M | Buy |
1,151,304
+104,747
| +10% | +$8.1M | 0.02% | 807 |
|
|
2017
Q4 | $59.8M | Buy |
1,046,557
+114,401
| +12% | +$7.2M | 0.01% | 1152 |
|
|
2017
Q3 | $62.2M | Buy |
932,156
+251,063
| +37% | +$15.1M | 0.02% | 1128 |
|
|
2017
Q2 | $35M | Buy |
681,093
+31,969
| +5% | +$1.63M | 0.01% | 1509 |
|
|
2017
Q1 | $37.9M | Buy |
649,124
+572,579
| +748% | +$27.4M | 0.01% | 1411 |
|
|
2016
Q4 | $3.19M | Buy |
76,545
+18,938
| +33% | +$994K | ﹤0.01% | 3435 |
|
|
2016
Q3 | $3.04M | Buy |
57,607
+15,291
| +36% | +$666K | ﹤0.01% | 3462 |
|
|
2016
Q2 | $1.77M | Buy |
42,316
+2,423
| +6% | +$120K | ﹤0.01% | 3723 |
|
|
2016
Q1 | $1.62M | Buy |
39,893
+24,930
| +167% | +$1.07M | ﹤0.01% | 3670 |
|
|
2015
Q4 | $971K | Sell |
14,963
-13,100
| -47% | -$859K | ﹤0.01% | 4329 |
|
|
2015
Q3 | $1.98M | Buy |
28,063
+3,265
| +13% | +$319K | ﹤0.01% | 3805 |
|
|
2015
Q2 | $2.76M | Buy |
24,798
+10,383
| +72% | +$1.12M | ﹤0.01% | 3520 |
|
|
2015
Q1 | $1.36M | Sell |
14,415
-18,504
| -56% | -$2.07M | ﹤0.01% | 4171 |
|
|
2014
Q4 | $3.69M | Buy |
32,919
+12,507
| +61% | +$1.12M | ﹤0.01% | 3266 |
|
|
2014
Q3 | $1.25M | Buy |
20,412
+15,136
| +287% | +$652K | ﹤0.01% | 4385 |
|
|
2014
Q2 | $242K | Buy |
+5,276
| New | +$215K | ﹤0.01% | 6044 |
|
|
2014
Q1 | – | Sell |
-10,812
| Closed | -$259K | – | 6745 |
|
|
2013
Q4 | $259K | Buy |
+10,812
| New | +$246K | ﹤0.01% | 5796 |
|
Other funds holding AGIO
FCM
LCM
AC
EAM
NAMI
Goldman Sachs's AGIO Position: Q2 2026 in Review
Goldman Sachs increased its Agios Pharmaceuticals (AGIO) stake by 43% in Q2 2026, buying an estimated $10.5M and bringing the position to 1,150,932 shares worth $42.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1949.
Goldman Sachs first reported a position in AGIO in Q4 2013 and has held it in 50 quarters since. The position peaked at $110M in Q1 2019. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.
- Goldman Sachs held 1,150,932 shares of Agios Pharmaceuticals worth $42.7M as of Q2 2026.
- Goldman Sachs bought 345,156 Agios Pharmaceuticals shares in Q2 2026, an estimated $10.5M.
- Agios Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1949 holding.
- Goldman Sachs first reported a position in Agios Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
- Goldman Sachs's Agios Pharmaceuticals position peaked at $110M in Q1 2019.
- 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.